Home>Topics>Stocks>Novo Nordisk A>Novo Nordisk A/S ADR

Novo Nordisk A/S ADR NVO

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Sanofi Shakes Off Patent Losses

      Headlines

      Mon, 24 Nov 2014

      generation basal insulins, including Sanofi's Toujeo. However, we believe competition from Eli Lilly LLY and Novo Nordisk NVO in the next-generation basal insulin market will be largely rational, which suggests stronger pricing power could return to

    2. Finding a Margin of Safety in a Fully Valued Market

      Headlines

      Fri, 21 Nov 2014

      contributing to its low uncertainty rating. However, new competition for Advate from the likes of Biogen Idec BIIB and Novo Nordisk NVO over the next few years could begin to erode the firm's dominant position in the U.S. market for hemophilia A products if

    3. 6 Key Concepts to Stock Investing Defined

      Headlines

      Thu, 6 Nov 2014

      duplicating a company’s products. For example, patents protect the excess returns of pharmaceutical manufacturers like Novo Nordisk NVO and Johnson & Johnson JNJ, and consumer products firms like Unilever UL and Coca-Cola KO can charge higher prices because

    4. A Preview of the 2014 Morningstar International-Stock Fund Manager of the Year Competition

      Headlines

      Tue, 4 Nov 2014

      strategies, have made lots of good picks in the health-care sector and the Indian market. Top-five holdings Novo Nordisk NVO and Novartis NVS have produced double-digit gains, for example, as have HDFC Bank HDB and Housing Development Finance Corp

    5. From Barron’s, October 27, 2014 (Part 1)

      Commentary

      Sat, 25 Oct 2014

      country funds is tricky and not recommended. The MSCI Europe Index is flat YTD, but Denmark is up +20% [ EDEN +10% ]; NVO is 40% of the index. Weakening euro should help European industrials and consumer-discretionary sectors. Mentioned are JEREX

    6. Moats and Growth Drivers Look Solid for Post-Split Baxter

      Headlines

      Sun, 15 Jun 2014

      1 million, and works only 70% of the time; if ITI fails, patients must move to a bypass therapy, like Novo Nordisk 's NVO NovoSeven or Baxter's Feiba, for life. We think Biogen lacks the long-term data in previously untreated patients to reassure

    7. Makings of a Wide Moat in Diabetes Care

      Headlines

      Fri, 28 Mar 2014

      rate (which incorporates sales of generic products like metformin), but lower than growth in more recent years ( Novo Nordisk NVO cites a 14.1% five-year historical market growth rate). Overall, while the tremendous U.S. pricing power of 2013 will

    8. Strong Pipeline Helps Protect Baxter's Wide Moat From Competition

      Headlines

      Mon, 30 Dec 2013

      product in 2014 that could support once-weekly dosing schedule (Advate can be given every three days), and Novo Nordisk NVO has filed for approval of a recombinant Factor VIII and has a long-acting version in late-stage development. However, Baxter

    9. Here's Flakey's own iteration of the total stock market index

      Commentary

      Wed, 4 Sep 2013

      cyclical/2.322% in each CHD, FHCO, JJSF and VLGEA/consumer defensive/2.55% in each ATRI, GILD, IDXX, MLAB, NVO and PRGO/healthcare/2.147% in each ATNI/communication services/3.83%; and lastly CERN, CNQR, TYL/technology

    10. What We Can Expect From Second-Quarter Earnings

      Video Reports

      Fri, 5 Jul 2013

      for your watchlist if we do see this volatility? Brilliant: I think there are a few that look pretty interesting. [TICKER: NVO ] Novo Nordisk is actually a Europe-based health-care company exposed to diabetes. They make a lot of insulin, and they

      NVO found at 4:46

      this volatility? Brilliant: I think there are a few that look pretty interesting. [TICKER: NVO ] Novo Nordisk is actually a Europe-based health-care company exposed to diabetes. They make a lot of insulin, and they really benefit from
    « Prev12345Next »
    Content Partners